The 82x ROI Claim Every Oncology Sponsor Is About to Misread
Tufts CSDD puts 82x ROI on AI monitoring agents in Phase 3 oncology. Before sponsors restructure monitoring teams, sites...
Risk-Based Monitoring
The 82x ROI Claim Looks Great on a Slide Deck — But Who’s Paying for the Infrastructure at the Site?
Tufts CSDD says AI monitoring agents deliver 82x ROI in Phase 3 oncology. But that number assumes sites can...
When Your CRO’s AI Sends a Query, Who’s Accountable for the Answer?
ICON's Anthropic partnership deploys Claude into clinical trial monitoring. Here's what site coordinators and ops leads need to verify...
What Icon’s $300M Microsoft Bet Means for the Sites Running Their Trials
Icon's enterprise-wide Microsoft Copilot deployment and $300M AI investment will reshape how CRAs monitor, query, and escalate — here's...